Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bheema Singu

Gastroenterology Ocala, FL Medical Doctor

NPI 1922204528 CMS profile 132665

7558 Sw 61St Ave, Suite 1, Ocala, FL 34476

Open in the dashboard

General payments

$5,148

228 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bheema Singu of Ocala, FL is reported in the CMS Open Payments database as having received $5,148 across 228 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $640 37
2024 General $1,432 51
2023 General $607 31
2022 General $419 25
2021 General $528 22
2020 General $602 28
2019 General $921 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bheema Singu
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Bheema Singu were reported at $640. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Bheema Singu Gastroenterology median Middle half National median
2019 $921 $417 $126–$1,100 $163
2020 $602 $224 $74–$624 $114
2021 $528 $352 $106–$1,054 $132
2022 $419 $448 $129–$1,270 $149
2023 $607 $533 $150–$1,390 $160
2024 $1,432 $605 $160–$1,606 $164
2025 $640 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,341 77 payments
  2. Ironwood Pharmaceuticals, Inc $784 21 payments
  3. Braintree Laboratories, Inc. $370 9 payments
  4. Phathom Pharmaceuticals, Inc. $285 24 payments
  5. Boston Scientific Corporation $272 6 payments
  6. Nestle HealthCare Nutrition Inc. $227 12 payments
  7. Medtronic, Inc. $159 4 payments
  8. Allergan Inc. $151 12 payments
  9. Aimmune Therapeutics, Inc. $144 6 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $141 9 payments
  11. Other $1,274 48 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,832 223 payments
  2. Gift $299 4 payments
  3. Consulting Fee $17 1 payment
Products named General payments · program years 2019–2025
  1. LINZESS Gastroenterology $1,746 72 payments
  2. CREON $684 47 payments
  3. ZENPEP $371 18 payments
  4. Linzess Gi $359 15 payments
  5. VIBERZI $271 12 payments
  6. MAVYRET $222 11 payments
  7. VOQUEZNA $177 9 payments
  8. SUFLAVE $164 2 payments
  9. DUPIXENT $127 4 payments
  10. XARELTO $124 1 payment
  11. Other $2,291 101 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

923

Median for Internal Medicine: 777

Drug cost

$353,744

Median for Internal Medicine: $73,373

Branded share of claims

40.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 32 $114,419
Zenpep Lipase/Protease/Amylase Brand 28 $109,849
Linzess Linaclotide Brand 87 $76,453
Voquezna Vonoprazan Fumarate Brand 32 $24,786
Cholestyramine Cholestyramine (With Sugar) Brand 122 $8,668
Pantoprazole Sodium Generic 269 $3,480
Budesonide Dr Budesonide Brand 14 $2,152
Ondansetron Hcl Generic 45 $2,064
Mesalamine Generic 12 $1,996
Sucralfate Generic 28 $1,798

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$344,251

Medicare's payments for the services billed

Medicare patients

1,170

Average age 75

Services billed

2,992

668 women, 502 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Ischemic heart disease 51%
Diabetes 44%
Chronic kidney disease 39%
Depression 35%
Heart failure 32%
Atrial fibrillation 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $234
$234 32 —
DUPIXENT
  • GENZYME CORPORATION $127
  • Regeneron Healthcare Solutions, Inc. $48
$174 — —
SUFLAVE
  • Braintree Laboratories, Inc. $164
$164 14 —
LINZESS
  • AbbVie, Inc. $67
  • Ironwood Pharmaceuticals, Inc $58
$125 87 —
XARELTO
  • Janssen Pharmaceuticals, Inc $124
$124 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

228 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record